

Supporting Information

Sequential Bioorthogonal Dual Strategy: ManNAI and SiaNAI as distinct tools to unravel sialic acids metabolic pathways

P.A. Gilormini, C. Lion, D. Vicogne, T. Levade, S. Potelle, C. Mariller, Y. Guérardel,
C. Biot, * and F. Foulquier *

11th January 2016

Note added after first publication: This Supplementary Information file replaces that originally published on 5th January 2016. In this version the previously omitted NMR, IR spectra and additional references are added.

General methods and materials

Synthetic procedures

Synthesis of ManNAI

Synthesis of SiaNAI

Imaging experiments

Cell culture

Metabolic labelling with alkyne tagged analogs

Imaging

Supplementary figures

Quantification of sialic acids

DMB derivatization

HPLC

NMR spectra of synthetic products

Infrared spectra


Additional references

General methods and materials


Chemicals reagents were purchased from Sigma Aldrich, TCI and Carbosynth and were used with no further purification. Anti-TGN46 and anti-EEA1 antibodies were from BD Biosciences (Franklin lakes, NJ, USA). Anti LAMP2 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Reactions were monitored by TLC on pre-coated TLC sheets ALUGRAM XtraSil from Macherey-Nagel. Detection was under UV light (254 nm) or by revelation with a solution of phosphomolybdic acid or a solution of vanillin / H_2SO_4 . Flash chromatography was performed on Interchim Puriflash 430. Silica column were purchased from Interchim (30 μm) or Macherey-Nagel (50 μm). Final products were freeze-dried before being characterized. ^1H NMR (1D, 2D) and ^{13}C NMR were recorded on a Bruker advanced DPX 300 MHz bearing a BBFO probe. NMR spectra were recorded in CDCl_3 or D_2O purchased from Eurisotop, chemical shifts are given in ppm relative to solvent peaks and coupling constants (J) are reported in hertz. MALDI-TOF experiments were performed on a 4800 Proteomics Analyzer mass spectrometer (Applied Biosystems, Framingham, MA, USA) in reflectron positive mode. Dihydroxybenzoic acid (DHB) was used as a matrix. Infrared spectra were recorded on a MIRacle10 (Shimadzu) with an ATR probe. Melting points were measured with SMP30 (Stuart).

Synthetic procedures

Scheme S1. Synthesis of ManNAI



Synthesis of *N*-(4-pentynoyl) mannosamine (ManNAI)^{1,2}



4-pent-ynoic acid (502 mg, 5.1 mmol, 1 eq.) was solved into CH₂Cl₂ (25 mL). N-hydroxysuccinimide (674 mg, 5.8 mmol, 1.14 eq.) and EDC or 1-ethyl (3-dimethylaminopropyl)carbodiimide (1.96 g, 10.2 mmol, 2eq.) were slowly added. The mixture was stirred for 3h30 at room temperature. The end of reaction was confirmed by TLC (cyclohexane/AcOEt ; 70 : 30). The solution was then washed four times with KHSO₄ (aqueous solution 2.8%). The recombined organic layers were dried over sodium sulfate, filtered and then concentrated under reduced pressure to give the succinimidyl ester as a white solid (875.3 mg, 4.48 mmol, 88 %). The product was used in the next step without further purification.

The coupling reaction with Mannosamine hydrochloride was conducted under nitrogen atmosphere. Hydrochloride D-Mannosamine (759 mg, 3.52 mmol, 1 eq.) and the succinimidyl ester from previous step (688 mg, 3.52 mmol, 1 eq.) were solved into DMF (25 mL). Triethylamine (1.4 mL, 10.77 mmol, 3 eq.) was slowly added. The mixture was stirred overnight. DMF was then removed under reduced pressure and the crude product was purified by flash chromatography (silica column, 40 g, 30 μm) with an elution by CH₂Cl₂ / EtOAc / MeOH ; 45 : 45 : 10). Solvents were then eliminated to yield ManNAI as a white solid (830 mg, 3.34 mmol, 95 %).


NMR: Mixture of anomers ($\alpha / \beta \approx 60\% / 40\%$). α ^1H NMR (300 MHz, D_2O): $\delta = 5.00$ (d, $J=1.4$, 1H, H_1), 4.23 (dd, $J=4.7, 1.4$, 1H, H_2), 3.93 (dd, $J=9.8, 4.7$, 1H, H_3), 3.80 – 3.62 (m, 3H, H_5 & H_6), 3.50 (t, $J=9.6$, 1H, H_4), 2.58 – 2.32 (m, 4H, H_8 & H_9), 2.26 (t, $J=2.3$, 1H, H_{11}). ^{13}C NMR (75 MHz, D_2O): $\delta = 175.26$ (C_7), 93.17 (C_1), 83.43 (C_{10}), 71.94 (C_5), 70.14 (C_{11}), 68.73 (C_3), 66.72 (C_4), 60.36 (C_6), 53.15 (C_2), 34.10 (C_8), 14.40 (C_9). β ^1H NMR (300 MHz, D_2O): $\delta = 4.90$ (d, $J=1.6$, 1H, H_1), 4.35 (dd, $J=4.4, 1.4$, 1H, H_2), 3.82 – 3.61 (m, 3H, H_3 & H_6), 3.40 (t, $J=9.8$, 1H, H_4), 3.29 (ddd, $J=9.9, 4.8, 2.3$, 1H, H_5), 2.53 – 2.31 (m, 4H, H_7 & H_8), 2.26 (t, $J=2.3$, 1H, H_{11}). ^{13}C NMR (75 MHz, D_2O): $\delta = 175.98$ (C_7), 92.84 (C_1), 83.85 (C_{10}), 76.28 (C_5), 71.96 (C_3), 69.99 (C_{11}), 66.45 (C_4), 60.36 (C_6), 53.98 (C_2), 34.25 (C_8), 14.26 (C_9).

m/z: calculated: $[\text{M} + \text{Na}]^+ = 282.247$; measured: 282.041.


m.p.: 36.5 – 39 °C.

Combustible elemental analysis: calculated C, 50.96; H, 6.61; N, 5.40; measured C, 51.02; H, 6.58; N, 5.38.

Scheme S2. Synthesis of SiaNAI



Synthesis of *N*-4-pentynylneuraminic acid (SiaNAI)³



ManNAI, (60 mg, 0.23 mmol, 1 eq.), sodium pyruvate (46 mg, 0.345 mmol, 2 eq.) and Neuraminic₅Ac aldolase (Sigma Aldrich EC 4.1.3.3) from *E. Coli* K12 (5 units dissolved in 0.1 mL) were added into 600 μL of phosphate buffer (KH_2PO_4 , 10.3 mM, K_2HPO_4 , 52.8 mM and MgCl_2 20 mM, pH – 7.5) into a reaction tube which was incubated at 37.5°C with moderate shaking (140

rpm) for 18 hours. The reaction completion was monitored by TLC (propan-1-ol / 25% Ammonia / H₂O ; 6 : 1 : 2.5). Reaction was quenched by the addition of 30 mL of water. The product was purified on an anion exchange resin (Bio-Rad AG1X2) activated with NH₄HCO₃ 0.1M. The sample was loaded on the column which was washed with H₂O (5 CV). Elution was performed with aqueous NH₄HCO₃ (0.05M, 5 CV) and then NH₄HCO₃ (0.2M, 5 CV). Fractions were detected by TLC (same elution as for the reaction monitoring) combined and freeze dried. After being solved into H₂O (1mL), sample was passed through a gel filtration column (P2) and then freeze dried again. SiaNAI was obtained as white powder (73 mg, 0.21 mmol, 91 %).

NMR: ¹H NMR (600 MHz, D₂O): δ = 3.96 – 3.86 (m, 2H, H₄ & H₉), 3.83 (t, J =10.1, 1H, H₅), 3.72 (dd, J =11.9, 2.7, 1H, H₉), 3.64 (ddd, J =9.2, 6.7, 2.7, 1H, H₈), 3.51 (d, J =9.2, 1H, H₇), 3.49 – 3.43 (m, 1H, H₉'), 2.47 – 2.34 (m, 4H, H₁₁ & H₁₂), 2.28 (d, J =2.0, 1H, H₁₃), 2.10 (dd, J =13.0, 4.9, 1H, H_{3eq}), 1.70 (dd, J =12.7, 11.7, 1H, H_{3ax}). ¹³C NMR (75 MHz, D₂O): δ 175.43 (C₁), 172.91 (C₁₀), 95.16 (C₂), 83.54 (C₁₃), 70.40 (C₁₄), 70.37 (C₈), 70.23 (C₆), 68.29 (C₇), 66.45 (C₄), 63.21 (C₉), 52.04 (C₅), 38.79 (C₃), 34.67 (C₁₁), 14.53 (C₁₂).

m/z: calculated: [M]⁺ = 346.312 ; measured: 346.017

m.p.: 26 – 28.5 °C

Combustible elemental analysis: calculated C, 48.41; H, 6.09; N, 4.04; measured C, 48.87 H, 5.89; N, 4.12.

BTAA was synthesized as previously described by Peng Wu *et al.*⁴

Imaging experiments

Cell culture

Primary skin fibroblasts and sialin deficient patient cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Lonza) at 37°C in humidity saturated 5% CO₂ atmosphere.

Metabolic labeling with alkyne tagged analogs

Fibroblasts were grown overnight on glass coverslips (12 mm diameter). Medium was then changed with pre-warmed medium containing 500 µM of modified sugar (SiaNAI or ManNAI). The labeling was stopped at the different time points mentioned by fixing the cells with 4% paraformaldehyde (PAF). Cells were then permeabilized in 0.5% Triton X-100 for 10 min. Permeabilized cells were then incubated with 100 µL/coverslip of a freshly prepared click solution (K₂HPO₄, 100 mM ; Sodium ascorbate, 2.5 mM ; CuSO₄, 150 µM ; BTAA, 300 µM, AzidoFluor 545, 10 µM). CuAAC was performed during 45 min, in the dark, at room temperature with gentle shaking. After 2h saturation in blocking buffer (0.2 % gelatin, 1% BSA and 2% normal goat serum (Invitrogen) in PBS), fixed cells were incubated at room temperature for 1h with primary antibodies (Molecular Probes) diluted at 1/100 in blocking buffer. Finally, cells were incubated at room temperature for 1h with Alexa 488-, Alexa 568-, and Alexa 700-conjugated secondary antibodies (Molecular Probes) diluted at 1/600 in blocking buffer.

Imaging

Immunostaining and fluorescent proteins were detected through an inverted Leica TCS-SP₅ confocal microscope. Pictures were taken by using Leica Application suite Advanced Fluorescence (LAS AF) software (Leica Microsystems Wetzlar, Germany). For comparison purposes, each picture has been taken under the same settings. For quantification, we used the Leica TCS-SP₅ intensity plotting tool that provides relative fluorescence intensities in different collection channels over a region of interest (ROI). Plot of fluorescence intensity in a ROI corresponding to the Golgi region has been performed for each cell. For image analysis, three different field of two independent experiments were examined. Around 100 cells have been quantified. The LAS AF pictures were then exported in TIFF format and processed with Adobe Photoshop 7.0.




Figure S11. Fibroblasts from healthy individuals were metabolically labelled with 500 µM of SiaNAI or ManNAI for 3, 6 and 8h respectively and stained with AzidoFluor 545 fluorescent probe (sialic acid into glycoconjugates in red) or antibodies against a late Golgi marker (TGN46 in blue) and an early endosomal marker (EEA1 in green). Staining was then visualized using confocal microscopy.




Figure S12. Fibroblasts from healthy individuals were metabolically labeled for 6h with 500 μ M of ManNAI in absence (0mM) or in presence of 5mM or 10mM of glucosamine, mannose, mannosamine and N-acetylmannosamine respectively. Cells were stained with AzidoFluor 545 fluorescent probe (sialic acid into glycoconjugates in red) and visualized by confocal microscopy.

Quantification of sialic acids



DMB derivatization⁵



Primary skin fibroblasts and sialin deficient cells were grown into T75 Flask. At confluence, cells were labelled with SiaNAI during 8h as previously described. Both primary skin and sialin deficient cells were also incubated without SiaNAI as negative controls. After incubation, all cells were scrapped with a rubber policeman in PBS. After being washed, cells were centrifuged at 3000 rpm and supernatant was removed. Cells were lysed with 100 μ L ultrapure water and then centrifuged at 3000 rpm for 10 min. In supernatant were found soluble glycoproteins and free saccharides whereas in the pellet were contained membrane glycoproteins and glycolipids. Supernatant was removed, added to 900 μ L of ethanol and kept overnight at -20°C in order to precipitate glycoproteins. After another centrifugation at 10000 rpm for 10 minutes, supernatant was removed and the pellet was pooled with the glycoproteins and glycolipids previously extracted. Then, this fraction was submitted to hydrolysis by addition of 100 μ L of trifluoroacetic acid (TFA) 0.1 M during 2 h at 80 °C. All samples were then dried into a vacuum concentrator (Concentrator 5301, Eppendorf).

1,2-diamino-4,5-methylenedioxybenzene dihydrochloride (DMB) reaction solution (β -mercapto-ethanol, 1M ; Na₂S₂O₄, 0.018M, TFA 0.02 M and DMB, 7 mM in water) was prepared. Dried samples were treated with 50 μ L of DMB reaction solution and 50 μ L of TFA 0.01 M and then incubated for 2 h in the dark. Samples were then diluted before being analyzed by HPLC.


HPLC

Analysis were performed on a Varian Prostar HPLC. 20 μL of sample was injected each time onto a Shodex C18 M4-E column (250 x 4.6 mm). The column was heated at 50°C during elution. Mobile was composed of two elution buffer: H₂O / Acetonitrile / MeOH (84 : 9 : 7) (A) and Acetonitrile / MeOH (1 : 1) (B). Elution method was the following: 100% A until 20 min, 100% A to 50% A until 28 minutes, 50% A during 5 min and then from 50% to 95% A in 1 min. A step at 95% A for 5 min and then back to 100% of A during 30 minutes for column equilibration. Derivatized sugars were detected by a ProStar Varian fluorescent detector (λ_{ex} : 372 nm / λ_{em} : 456 nm).







May 28-2014-BIOC




Mar 28, 2014-BIOC







ManNAI



SiaNAI



References

- 1 E. D. Funder, A. B. Jensen, T. Tørring, A. L. B. Kodal, A. R. Azcargorta and K. V. Gothelf, *J. Org. Chem.*, 2012, **77**, 3134.
- 2 T.-L. Hsu, S. R. Hanson, K. Kishikawa, S.-K. Wang, M. Sawa and C.-H. Wong, *Proc. Natl. Acad. Sci.*, 2007, **104**, 2614.
- 3 P. V. Chang, X. Chen, C. Smyrniotis, A. Xenakis, T. Hu, C. R. Bertozzi and P. Wu, *Angew. Chem. Int. Ed.*, 2009, **48**, 4030.
- 4 C. Besanceney-Webler, H. Jiang, T. Zheng, L. Feng, D. Soriano del Amo, W. Wang, L. M. Klivansky, F. L. Marlow, Y. Liu and P. Wu, *Angew. Chem. Int. Ed.*, 2011, **50**, 8051.
- 5 S. Hara, Y. Takemori, M. Yamaguchi, M. Nakamura and Y. Ohkura, *Anal. Biochem.*, 1987, **164**, 138.